HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

John Lunec Selected Research

nutlin 3

12/2018ATM Dependent DUSP6 Modulation of p53 Involved in Synergistic Targeting of MAPK and p53 Pathways with Trametinib and MDM2 Inhibitors in Cutaneous Melanoma.
1/2018Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma.
9/2017Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer.
11/2016Nutlin-3 inhibits androgen receptor-driven c-FLIP expression, resulting in apoptosis of prostate cancer cells.
6/2016Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer.
6/2007Analysis of the MDM2 antagonist nutlin-3 in human prostate cancer cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


John Lunec Research Topics

Disease

21Neoplasms (Cancer)
07/2021 - 07/2003
16Neuroblastoma
01/2019 - 08/2002
3Osteosarcoma (Osteogenic Sarcoma)
02/2021 - 03/2012
3Sarcoma (Soft Tissue Sarcoma)
05/2014 - 03/2005
2Carcinoma (Carcinomatosis)
02/2021 - 01/2018
2Neoplasm Metastasis (Metastasis)
02/2021 - 08/2014
2Melanoma (Melanoma, Malignant)
12/2018 - 01/2018
2Ovarian Neoplasms (Ovarian Cancer)
09/2017 - 06/2016
2Prostatic Neoplasms (Prostate Cancer)
11/2016 - 06/2007
1Hepatitis
10/2021
1Adenocarcinoma
07/2021
1Hypoxia (Hypoxemia)
02/2021
1Fibrosis (Cirrhosis)
01/2021
1Inflammation (Inflammations)
01/2021
1Biliary Tract Neoplasms (Biliary Tract Cancer)
10/2020
1Ataxia Telangiectasia (Louis Bar Syndrome)
10/2020
1Colorectal Neoplasms (Colorectal Cancer)
01/2020
1Head and Neck Neoplasms (Head and Neck Cancer)
04/2019
1Uterine Cervical Neoplasms (Cancer of the Cervix)
05/2016
1Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
09/2015
1Metabolic Diseases (Metabolic Disease)
12/2012
1Mesothelioma
06/2009
1Malignant Mesothelioma
06/2009

Drug/Important Bio-Agent (IBA)

8RG7388IBA
01/2019 - 04/2015
6nutlin 3IBA
12/2018 - 06/2007
5Proteins (Proteins, Gene)FDA Link
02/2021 - 04/2019
3RNA (Ribonucleic Acid)IBA
10/2021 - 09/2007
3siremadlinIBA
07/2021 - 01/2018
3Biomarkers (Surrogate Marker)IBA
09/2015 - 03/2012
3Tumor Suppressor Protein p14ARF (p14ARF)IBA
04/2015 - 02/2006
3Messenger RNA (mRNA)IBA
01/2013 - 07/2003
2GSK2830371IBA
07/2021 - 01/2018
2Matrix Metalloproteinases (MMPs)IBA
02/2021 - 07/2003
2NucleotidesIBA
01/2020 - 04/2019
2Temozolomide (Temodar)FDA LinkGeneric
01/2019 - 04/2015
2Dihydroorotate DehydrogenaseIBA
01/2018 - 01/2018
2Pharmaceutical PreparationsIBA
01/2018 - 03/2012
2Androgen Receptors (Androgen Receptor)IBA
11/2016 - 06/2007
2Cisplatin (Platino)FDA LinkGeneric
06/2016 - 04/2015
2Pemetrexed (MTA)FDA Link
09/2015 - 12/2009
2Tretinoin (Retinoic Acid)FDA LinkGeneric
01/2013 - 11/2007
2N-acetyltalosaminuronic acid (NAT)IBA
12/2012 - 08/2003
2Biological ProductsIBA
03/2012 - 08/2002
2Transcription Factors (Transcription Factor)IBA
07/2010 - 07/2003
2LuciferasesIBA
03/2008 - 07/2003
23- (4- chlorophenyl)- 3- (4- hydroxy- 3,5- dimethoxybenzyloxy)- 2- propyl- 2,3- dihydroisoindol- 1- oneIBA
10/2006 - 03/2005
1Phosphoric Monoester Hydrolases (Phosphatases)IBA
07/2021
1Oxygen (Dioxygen)IBA
02/2021
1Matrix Metalloproteinase 14 (MT1-MMP)IBA
02/2021
1AntioxidantsIBA
01/2021
1Blood Glucose (Blood Sugar)IBA
01/2021
1LigandsIBA
01/2021
1GemcitabineFDA Link
10/2020
1RO6839921IBA
01/2019
1ProdrugsIBA
01/2019
1Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
12/2018
1trametinibIBA
12/2018
1Coloring Agents (Dyes)IBA
01/2018
14,4- difluoro- 4- bora- 3a,4a- diaza- s- indacene (BODIPY)IBA
01/2018
1VimentinIBA
01/2018
1Keratins (Keratin)IBA
01/2018
1rucaparibIBA
09/2017
1Adenosine Diphosphate (ADP)IBA
05/2016
1Poly(ADP-ribose) Polymerase InhibitorsIBA
05/2016
1Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA
05/2016
1Adenosine Diphosphate Ribose (ADP-Ribose)IBA
05/2016
1Lapatinib (GW572016)FDA Link
09/2015
1Thymidylate SynthaseIBA
09/2015
1Topotecan (Hycamtin)FDA LinkGeneric
04/2015
1Busulfan (Busulfex)FDA Link
04/2015
1Doxorubicin (Adriamycin)FDA LinkGeneric
04/2015
1Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA
08/2014
1Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA
08/2014
1Celecoxib (Celebrex)FDA Link
08/2014
1RG7112IBA
05/2014
1Glucose (Dextrose)FDA LinkGeneric
12/2012
1Fatty Acids (Saturated Fatty Acids)IBA
12/2012
1Glutamine (L-Glutamine)FDA Link
12/2012
1Folic Acid AntagonistsIBA
12/2009
1Indicators and Reagents (Reagents)IBA
12/2009
1Growth Factor ReceptorsIBA
06/2009
1orantinib (SU6668)IBA
06/2009
1Tyrosine Kinase InhibitorsIBA
06/2009
1vandetanib (ZD6474)IBA
06/2009
1vatalanib (PTK787)IBA
06/2009
1Sunitinib (Sutent)FDA Link
06/2009
1Gefitinib (Iressa)FDA Link
06/2009
1Monoclonal AntibodiesIBA
10/2007
1ParaffinIBA
10/2007
1Formaldehyde (Formol)FDA Link
10/2007
1AntibodiesIBA
09/2007
1Proto-Oncogene Proteins c-mdm2IBA
09/2007
1Small Interfering RNA (siRNA)IBA
05/2007

Therapy/Procedure

15Therapeutics
07/2021 - 07/2003
9Drug Therapy (Chemotherapy)
10/2020 - 07/2003
2Ligation
02/2021 - 02/2011
1Oral Administration
01/2021
1Molecular Targeted Therapy
01/2019
1Immunotherapy
03/2018
1Drug Tapering
09/2017